PetVivo Holdings Inc · OTC:PETV
PetVivo — Investor Presentation (January 2025)
24 slides from PetVivo's investor presentation, Jan 2, 2025
Slide 1: Investor Presentation January 2025
Investor Presentation January 2025 PETV (OTCGB) PetVivo Holdings, Inc.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary contains forward-looking statements within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those
Slide 3: Company Highlights
Company Highlights Focus on estimated $11B companion animal veterinary care and product sales market Spryng™, with our OsteoCushion™ Technology, is a veterinary device that promotes the restoration of joint mechanics for the management of lameness and other joint-related afflictions including osteoa
Slide 4: Osteoarthritis (OA) Opportunity
Osteoarthritis (OA) Opportunity $11B Veterinary Care and Product Sales Market Osteoarthritis: a common affliction of the joints ¢ Affects approximately 34 million adult dogs and 1 million horses* * Causes pain and inflammation from degenerated cartilage of stressed joints ¢ Lameness worsens with tim
Slide 5: The Optimal OA Solution: Spryng with OsteoCushion Technology
The Optimal OA Solution: Spryng with OsteoCushion Technology * Spryng provides a biocompatible lubricious and viscoelastic biomaterial, which promotes the restoration of joint mechanics to improve joint function - Similar components/function found in natural cartilage (i.e. collagen, elastin and hep
Slide 6: Spryng with OsteoCushion Technology
Spryng with OsteoCushion Technology * Spryng is a unique new medical device addressing the root cause of the affliction, not just the symptoms * Purified natural components self-assemble to form an insoluble, hydrated matrix - Protein source bovine tissues (i.e. collagen and elastin) from isolated h
Slide 7: Spryng Mechanism of Action
Spryng Mechanism of Action ° Ananimal suffering from osteoarthritis generally exhibits damaged and/or lost cartilage thereby creating bone on bone contact that results in an increase of joint inflammation, pain and further loss of cartilage * Spryng reinforces synovial membrane function, without pha
Slide 8: Spryng Canine Success: Buggy
CONDITION 13-year-old mixed breed. Last 2 years mobility issues have worsened. Led a very active lifestyle until the last 6 years exhibited painful mobility: offen trembled with movement. Unable to run and play outside with the other dogs as she loves to do. Orthopedic exam revealed decreased range-
Slide 9: Spryng Equine Case Study: Fergie
Spryng Equine Case Study: Fergie See other equine case studies online See Tinker Case Study here. 1) Results to vary per animal HISTORY 16-year-old Saddlebred mare. Fergie shows as a Saddlebred monthly and ridden 5-6 days per week. However, due to apparent discomfort, she had become choppy, awkward
Slide 10: Spryng Competitive Distinctions
Spryng Competitive Distinctions 4 Outcomes address affliction/not just symptoms * Current treatments rely on biologic activity to treat symptoms; Spryng provides structural components to address affliction ° Price/Cost advantage . Derived from all natural materials a) Ease of application s Vet clini
Slide 11: Spryng: Product Category Comparison
Spryng: Product Category Comparison *NSAIDs: Rimadyl *Orthobiologics FEATURES. PRP, APS Banamine Injections per Year AD 16-18 1 Benefits Last up to 12 Months. r x x x x v v or More Bioscaffold From Naturally-Derived Components x x us us a es No Synthetic or xX x Radioactive Material Research Support
Slide 12: Distribution Services Agreements: Cencora (MWI) and Covetrus
Distribution Services Agreements: Cencora (MWI) and Covetrus MWI — PetVivo Distribution Services Agreement Terms: . Non-exclusive distribution agreement with ongoing annual renewal option until terminated by either party * Designated distributor for PetVivo’s veterinary medical device, Spryng with O
Slide 13: Spryng Tolerance Studies
Spryng Tolerance Studies SPryNg’ with OsteoCushion” Technology rt Canine Tolerance Purpose: Assess tolerance of Spryng™ administration in dogs. Design: 20 healthy dogs received intra-articular injection with saline or Spryng in contralateral shoulder, hip, elbow, and stifle joints in a randomized se
Slide 14: Spryng Clinical Studies
Spryng Clinical Studies 6) spryng with OsteoCushion“Technology Canine Hip OA CASE ETHOS sekcinteatAtRettCy —VETERINA® Purpose: Study the effects of Collagen-Elastin Hydrogel Microparticles (Spryng) on pain & function secondary to hip osteoarthritis in dogs. Investigators: Colorado Animal Specialty &
Slide 15: New Spryng Clinical Trials
New Spryng Clinical Trials Underway or Recently Completed, Awaiting Publication & spryng with OsteoCushion“Technology Canine Study at Colorado State University Principal investigators: Felix Duerr, DVM, MS, Dr. med. vet, CCRT, DACVS-SA, DECVS, DACVSSMR Pilot study design: Pilot study evaluating intr
Slide 16: State-of-the-Art Production Facilities
State-of-the-Art Production Facilities ¢ Spryng product is manufactured in PetVivo’s ISO certified cleanrooms (ISO 8 to ISO 7 to ISO 5 ¢ Initial batch sizes of approx. 2,000 syringes; planning to increase to batches of 5,000+ syringes per month. °* Current production facility annual capacity is appr
Slide 17: Comprehensive IP Portfolio
Comprehensive IP Portfolio ¢ 12 US Patents and 9 Foreign Patents ¢ Broad Claim Language - “Comprising” Transitions * Our Patents & Trade Secrets Protect: Protein & Carbohydrate Based Thermoplastics Biomaterials of Many Compositions Medical, Drug Delivery & Combination Products Medical & Pharmaceutic
Slide 18: Pet Product Pipeline (FDA clearance not required)
Pet Product Pipeline (FDA clearance not required) Pro Commercial ee) soe nares | specie | ey J mice | emecey | Sr VD-01 Osteoarthritis Canine (Spryng™) Q3 2021 VD-02 Osteoarthritis Equine (Spryng™) Se) 932021 } VD-03 Digital Cushion Lameness Equine (Brand TDB) 2 VD-04 Urinary Incontinence Canine (Br
Slide 19: Market Overview: Companion Animal/Veterinarian
Market Overview: Companion Animal/Veterinarian * US Pet Spend increased from $123.6B in 2021 to $138.0B in 2022 Veterinary care and products is a leading growth driver - $11B in 2021 in US 66% of US Households own a pet - 83.0M Dogs; 50.0M Cats Approximately 7.2M horses in US* ° Pet owners’ spending
Slide 20: Management Team Introduction
Management Team Introduction Deep Bench of Industry Veterans with Decades of Experience ae @ John Lai Garry Lowenthal Randall Meyer John F. Dolan April Boyce Bryan S. Monninger CEO, President & Director CFO coo General Counsel vP of Marketing VP of Sales BlueEarth - . lial pwe c SA rRAUsT PG & Novus
Slide 21: Strong Board of Directors and Advisors
Strong Board of Directors and Advisors &0O@e@ee8@ BD Michael Eldred Joseph Jasper Robert Rudelius Director Director Director Diane Levitan Robert Costantino Spencer Breithaupt John Lai Director Director Director Director & CEO ———— Z (By esorae” |X medicametrix ey «| SMWrAnimal Heatth Noble Vent Pip
Slide 22: Growth Drivers
Growth Drivers ° Expand Sales Force and Distribution ¢ Add regional sales managers ¢ Distributor networks * Vetcove @ioec. 2021) * MWIDSA (June 2022) * Covetrus DSA (December 2023) ° Increase KOL Adoption ¢ Used by veterinarians in more than 600 clinics in 49 states * Podium presentations at confere
Slide 23: PetVivo Highlights
PetVivo Highlights 1" 2 va cy oe Large market opportunity - $11B Veterinary Care and Products Market and growing Increased humanization of companion animals driven by Covid-19 pandemic Spryng is an optimal solution for the management of OA over the current treatments Offers significant benefits for
Slide 24: John Lai
John Lai Chief Executive Officer jlai@petvivo.com (952) 405-6216 PetVivo.com To order, contact infol@petvivo.com or 844-PET-VIVO (844-738-8486) Spryng™ with OsteoCushion™ Technologyis a veletinary medical device by PelVivo, Inc. Spryng™ is a trademark of PetVivo Holdings, Inc. This product is covere
PetVivo Holdings — Investor Presentation (January 2025) on 6ix